CICC Maintains Outperform Rating on Sinopharm
CICC maintained its Outperform rating on Sinopharm.
Related stories
Reliance Industries Q2 Profit May Top Rs 21,000 Crore
Reliance Industries is expected to report September-quarter profit above Rs 21,000 crore, with refining and Jio cited as earnings drivers. The company is scheduled to announce resu
M impact | EQUITY | Oct 30, 2026, 04:11 AM UTC
Australian Energy Stocks Reach One-Week High as Oil Rises
Australian energy stocks reached a one-week high as supply concerns lifted oil prices.
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC
Nasdaq 100 futures fall 2%; S&P 500 futures down almost 1%
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC
U.S. Stock Futures Fall as Intel and Amazon Earnings Weigh
At 11:44 p.m. EDT, Dow futures fell 0.17%, S&P 500 futures fell 0.95% and Nasdaq-100 futures fell more than 2% after disappointing earnings from Intel and Amazon.
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC
Janome to Buy Back Up to 5.98% of Shares
L impact | EQUITY | Oct 30, 2026, 04:02 AM UTC
Asian session market picture: S&P 500 -0.94%, Nasdaq 100 -2.06%; USD/JPY -0.15%, WTI +1.18%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.94 percent, Nasdaq futures is down 2.06 percent, Dow futures is down 0.19 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 04:00 AM UTC